Avandamet

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
08-06-2016

Ingredient activ:

rosiglitazone, metformin hydrochloride

Disponibil de la:

SmithKline Beecham Plc

Codul ATC:

A10BD03

INN (nume internaţional):

rosiglitazone, metformin

Grupul Terapeutică:

Drugs used in diabetes

Zonă Terapeutică:

Diabetes Mellitus, Type 2

Indicații terapeutice:

AVANDAMET is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).

Rezumat produs:

Revision: 16

Statutul autorizaţiei:

Withdrawn

Data de autorizare:

2003-10-20

Prospect

                                Medicinal product no longer authorised
105
B. PACKAGE LEAFLET
Medicinal product no longer authorised
106
PACKAGE LEAFLET: INFORMATION FOR THE USER
AVANDAMET 1 MG/500 MG FILM-COATED TABLETS
AVANDAMET 2 MG/500 MG FILM-COATED TABLETS
AVANDAMET 2 MG/1000 MG FILM-COATED TABLETS
AVANDAMET 4 MG/1000 MG FILM-COATED TABLETS
rosiglitazone/metformin HCl
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
-
KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even
if their symptoms are the same as yours.
-
IF ANY OF THE SIDE EFFECTS GETS SERIOUS, OR IF YOU NOTICE ANY SIDE
EFFECTS NOT LISTED IN THIS
LEAFLET, TELL YOUR DOCTOR OR PHARMACIST.
IN THIS LEAFLET
:
1.
WHAT AVANDAMET IS AND WHAT IT IS USED FOR
2.
BEFORE YOU TAKE AVANDAMET
3.
HOW TO TAKE AVANDAMET
4.
POSSIBLE SIDE EFFECTS
5
HOW TO STORE AVANDAMET
6.
FURTHER INFORMATION
1.
WHAT AVANDAMET IS AND WHAT IT IS USED FOR
AVANDAMET TABLETS ARE A COMBINATION OF TWO DIFFERENT MEDICINES
called
_rosiglitazone_
and
_metformin. _
These two medicines are used to treat
TYPE 2 DIABETES.
People with type 2 diabetes either don’t make enough insulin (a
hormone that controls blood sugar
levels), or don’t respond normally to the insulin their body makes.
Rosiglitazone and metformin work
together so your body makes better use of the insulin it produces, and
this helps reduce your blood
sugar to a normal level. Avandamet can be used alone or with a
sulphonylurea, another medicine for
diabetes.
2.
BEFORE YOU TAKE AVANDAMET
To help manage your diabetes, it is important that you follow any diet
and lifestyle advice from your
doctor as well as taking Avandamet.
DON’T TAKE AVANDAMET:
•
IF YOU ARE ALLERGIC
(
_hypersensitive_
) to rosiglitazone or metformin or any of the other
ingredients of Avandamet (
_listed in Section 6)_
•
IF YOU HAVE HAD A HEART ATTACK OR SEVERE ANGINA,
that’s being treated in hospital
•

                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
AVANDAMET 1 mg/500 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each tablet contains 1 mg of rosiglitazone (as rosiglitazone maleate)
and 500 mg of metformin
hydrochloride (corresponding to metformin free base 390 mg).
Excipients:
Each tablet contains lactose (approximately 6 mg).
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Yellow film-coated tablets marked "gsk" on one side and "1/500" on the
other.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
AVANDAMET is indicated in the treatment of type 2 diabetes mellitus
patients, particularly
overweight patients:
-
who are unable to achieve sufficient glycaemic control at their
maximally tolerated dose of oral
metformin alone.
-
in triple oral therapy with sulphonylurea in patients with
insufficient glycaemic control despite
dual oral therapy with their maximally tolerated dose of metformin and
a sulphonylurea (see
section 4.4).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The usual starting dose of AVANDAMET is 4 mg/day rosiglitazone plus
2000 mg/day metformin
hydrochloride.
Rosiglitazone can be increased to 8 mg/day after 8 weeks if greater
glycaemic control is required. The
maximum recommended daily dose of AVANDAMET is 8 mg rosiglitazone plus
2000 mg metformin
hydrochloride.
The total daily dose of AVANDAMET should be given in two divided
doses.
Dose titration with rosiglitazone (added to the optimal dose of
metformin) may be considered before
the patient is switched to AVANDAMET.
When clinically appropriate, direct change from metformin monotherapy
to AVANDAMET may be
considered.
Taking AVANDAMET with or just after food may reduce gastrointestinal
symptoms associated with
metformin.
Triple oral therapy (rosiglitazone, metformin and sulphonylurea) (see
section 4.4)
Medicinal product no longer authorised
3
-
Patients on metformin and sulp
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului bulgară 08-06-2016
Raport public de evaluare Raport public de evaluare bulgară 08-06-2016
Prospect Prospect spaniolă 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului spaniolă 08-06-2016
Raport public de evaluare Raport public de evaluare spaniolă 08-06-2016
Prospect Prospect cehă 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului cehă 08-06-2016
Raport public de evaluare Raport public de evaluare cehă 08-06-2016
Prospect Prospect daneză 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului daneză 08-06-2016
Raport public de evaluare Raport public de evaluare daneză 08-06-2016
Prospect Prospect germană 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului germană 08-06-2016
Raport public de evaluare Raport public de evaluare germană 08-06-2016
Prospect Prospect estoniană 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului estoniană 08-06-2016
Raport public de evaluare Raport public de evaluare estoniană 08-06-2016
Prospect Prospect greacă 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului greacă 08-06-2016
Raport public de evaluare Raport public de evaluare greacă 08-06-2016
Prospect Prospect franceză 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului franceză 08-06-2016
Raport public de evaluare Raport public de evaluare franceză 08-06-2016
Prospect Prospect italiană 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului italiană 08-06-2016
Raport public de evaluare Raport public de evaluare italiană 08-06-2016
Prospect Prospect letonă 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului letonă 08-06-2016
Raport public de evaluare Raport public de evaluare letonă 08-06-2016
Prospect Prospect lituaniană 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului lituaniană 08-06-2016
Raport public de evaluare Raport public de evaluare lituaniană 08-06-2016
Prospect Prospect maghiară 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului maghiară 08-06-2016
Raport public de evaluare Raport public de evaluare maghiară 08-06-2016
Prospect Prospect malteză 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului malteză 08-06-2016
Raport public de evaluare Raport public de evaluare malteză 08-06-2016
Prospect Prospect olandeză 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului olandeză 08-06-2016
Raport public de evaluare Raport public de evaluare olandeză 08-06-2016
Prospect Prospect poloneză 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului poloneză 08-06-2016
Raport public de evaluare Raport public de evaluare poloneză 08-06-2016
Prospect Prospect portugheză 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului portugheză 08-06-2016
Raport public de evaluare Raport public de evaluare portugheză 08-06-2016
Prospect Prospect română 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului română 08-06-2016
Raport public de evaluare Raport public de evaluare română 08-06-2016
Prospect Prospect slovacă 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului slovacă 08-06-2016
Raport public de evaluare Raport public de evaluare slovacă 08-06-2016
Prospect Prospect slovenă 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului slovenă 08-06-2016
Raport public de evaluare Raport public de evaluare slovenă 08-06-2016
Prospect Prospect finlandeză 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului finlandeză 08-06-2016
Raport public de evaluare Raport public de evaluare finlandeză 08-06-2016
Prospect Prospect suedeză 08-06-2016
Caracteristicilor produsului Caracteristicilor produsului suedeză 08-06-2016
Raport public de evaluare Raport public de evaluare suedeză 08-06-2016

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor